Takeda Pharmaceutical (TAK) News Today $14.10 -0.21 (-1.47%) Closing price 10/9/2025 03:59 PM EasternExtended Trading$13.81 -0.29 (-2.06%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TAK Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Major pharmaceutical company announces new round of Greater Boston layoffsOctober 6, 2025 | msn.comTakeda Pharmaceutical Co. $TAK Shares Bought by QRG Capital Management Inc.October 6, 2025 | marketbeat.comTakeda, largest biopharma employer in Mass., announces more layoffsOctober 4, 2025 | bostonglobe.comBWith Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?October 3, 2025 | finance.yahoo.comTakeda Pharmaceutical unveils $170M expansion in Thousand OaksOctober 1, 2025 | msn.comTakeda Pharmaceutical to exit cell therapy researchOctober 1, 2025 | reuters.comBristol Myers, Takeda to pool data for AI-based drug discoveryOctober 1, 2025 | reuters.comMorgan Stanley Reaffirms Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)September 25, 2025 | theglobeandmail.comTakeda Announces Financial Reclassification to Enhance Capital FlexibilitySeptember 25, 2025 | msn.comTakeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion AnnuallySeptember 24, 2025 | seekingalpha.com20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 CountriesSeptember 23, 2025 | businesswire.com22,734 Shares in Takeda Pharmaceutical Co. $TAK Bought by Sivia Capital Partners LLCSeptember 19, 2025 | marketbeat.comGastroparesis Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome ...September 18, 2025 | theglobeandmail.comTakeda Flat on Hookup with VELASeptember 16, 2025 | baystreet.ca‘As close as one could get to living a near-normal life’: Experimental narcolepsy drugs bring hope to patientsSeptember 16, 2025 | bostonglobe.comBProtagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025September 15, 2025 | finance.yahoo.comBaird Financial Group Inc. Invests $276,000 in Takeda Pharmaceutical Co. $TAKSeptember 14, 2025 | marketbeat.comAntibody Drug Conjugates Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics ...September 11, 2025 | theglobeandmail.comTakeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High - Should You Buy?September 10, 2025 | marketbeat.comNikkei ends lower on yen strength, profit-taking after crossing 44,000September 9, 2025 | msn.comJapan's Nikkei rises to 44,000 for first time on trade, spending optimismSeptember 9, 2025 | msn.comAssessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia ExpansionSeptember 9, 2025 | finance.yahoo.comPromising Phase 3 Results for Takeda’s Oveporexton Boost Buy RatingSeptember 9, 2025 | tipranks.comTakeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comTakeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)September 8, 2025 | seekingalpha.comTakeda Pharmaceutical Company Limited (TAK) Special Call - SlideshowSeptember 8, 2025 | seekingalpha.comTakeda Nears First Therapy for Narcolepsy’s Root CauseSeptember 8, 2025 | bloomberg.comNomura Holdings Inc. Invests $338,000 in Takeda Pharmaceutical Co. $TAKSeptember 8, 2025 | marketbeat.comTakeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025September 8, 2025 | businesswire.comAdage Capital Partners GP L.L.C. Invests $51.05 Million in Takeda Pharmaceutical Co. $TAKSeptember 6, 2025 | marketbeat.comInvesco Ltd. Buys New Shares in Takeda Pharmaceutical Co. $TAKSeptember 6, 2025 | marketbeat.comU.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand DiseaseSeptember 5, 2025 | businesswire.comGraham Capital Management L.P. Buys New Stake in Takeda Pharmaceutical Co. $TAKSeptember 4, 2025 | marketbeat.comNorthern Trust Corp Sells 233,675 Shares of Takeda Pharmaceutical Co. $TAKSeptember 2, 2025 | marketbeat.comTakeda Pharmaceutical Co. $TAK Stock Holdings Increased by Russell Investments Group Ltd.September 1, 2025 | marketbeat.comTakeda Pharmaceutical Co. $TAK Shares Bought by Charles Schwab Investment Management Inc.August 31, 2025 | marketbeat.comCapital Fund Management S.A. Acquires New Shares in Takeda Pharmaceutical Co. $TAKAugust 29, 2025 | marketbeat.comTakeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer TreatmentsAugust 28, 2025 | insidermonkey.comHighTower Advisors LLC Sells 36,694 Shares of Takeda Pharmaceutical Co. $TAKAugust 28, 2025 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Lowered to Strong Sell Rating by Zacks ResearchAugust 25, 2025 | marketbeat.comJapanese pharma company Takeda to conduct clinical trials in India soonAugust 22, 2025 | msn.comTakeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Should You Buy?August 22, 2025 | marketbeat.comMyasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion ...August 21, 2025 | theglobeandmail.comJapan's Takeda weighs India for global trials to speed up drug launchesAugust 21, 2025 | reuters.comShort Interest in Takeda Pharmaceutical Co. (NYSE:TAK) Rises By 81.5%August 20, 2025 | marketbeat.comCorient IA LLC Purchases Shares of 40,000 Takeda Pharmaceutical Co. (NYSE:TAK)August 19, 2025 | marketbeat.comEthic Inc. Reduces Stake in Takeda Pharmaceutical Co. (NYSE:TAK)August 19, 2025 | marketbeat.comBoston Partners Raises Stake in Takeda Pharmaceutical Co. (NYSE:TAK)August 19, 2025 | marketbeat.comUS Bancorp DE Trims Position in Takeda Pharmaceutical Co. (NYSE:TAK)August 10, 2025 | marketbeat.comXY Capital Ltd Has $1.43 Million Position in Takeda Pharmaceutical Co. (NYSE:TAK)August 9, 2025 | marketbeat.com Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TAK Media Mentions By Week TAK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.390.77▲Average Medical News Sentiment TAK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼45▲TAK Articles Average Week Get the Latest News and Ratings for TAK and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SNY News Today GSK News Today ARGX News Today ONC News Today INSM News Today BNTX News Today TEVA News Today GMAB News Today SMMT News Today ASND News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TAK) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
